OTC Markets OTCPK - Delayed Quote - USD

Hypha Labs, Inc. (DIGP)

$0.0217 (0.00%)
OTC Markets OTCPK - Delayed Quote - USD

Hypha Labs, Inc. (DIGP)

$0.0217 (0.00%)

GROUND BREAKING TECHNOLOGY

Pioneering the Production of Psilocybin

What is Hypha Labs?

A revolutionary bioreactor the size of a coffee maker that can grow psilocybin in 7-10 days from the comfort of your home.

Hypha Labs Delivers Measurable Active Ingredients

Hyphalabs has developed technology that quickly cultivates the mycelium root structures of psilocybin mushrooms and other functional mushroom’s mycelium into a natural product.  This product has an exact, consistent potency containing all the natural compounds found in these fungi. Typically, it takes 6-8 weeks to fully grow mushrooms, and using Hyphalabs technology the production of the active ingredient is only 7-10 days. 

Your Image

Psychedelic & Functional Mushroom Sales Positioned to Reach $7.2B

Ever wonder about the incredible power locked within mushrooms? Well, wonder no more! At Hypha Labs, we’re on a mission to unleash mushrooms’ full potential for mental and physical well-being. From psychedelic wonders to functional marvels, we harness nature’s finest to bring innovative solutions for a healthier, happier life.

Our Patented Technology Catalyzing A $3.6 B Psilocybin Market

Our latest achievement is the filing of a new patent. This marks a significant milestone in the realm of mycological innovation. In 2022, the U.S. market for functional and psychedelic mushrooms reached a valuation of USD $3.6 billion, with anticipated growth at a CAGR of 12.1% from 2023 to 2030. This upward trajectory aligns with the increasing momentum in the United States toward the decriminalization of not only psychedelic mushrooms, but the rapid growth and benefits of functional mushrooms.

Craig Ellins (Chief Science Officer)

Hypha Labs, Inc. has announced that it has made Craig Ellins its Chief Science Officer. Craig Ellins is a visionary in emerging technologies and industries, having founded and led companies like One World Pharma and GB Science.

Presenting at the Planet MicroCap Showcase

A global multimedia financial news, publishing and events company focused on news dissemination, providing information, data and analytics for the MicroCap investing community. 

Changing name from Digipath to Hypha Labs

Hypha Labs, Inc. has announced that it has changed its name from Digipath, Inc. after the sale of its cannabis lab assets. It has developed cutting edge technology focused on revolutionary methods of producing psilocybin.

Hypha Labs Announces New Patent Filing

Today marks a significant milestone in the realm of mycological innovation as Hypha Labs, Inc., a pioneer in functional mushroom sciences, proudly announces the initiation of a groundbreaking patent portfolio.

Microdosing &
The Brain

A rising trend in natural and holistic health practices has emerged, encompassing the utilization of natural substances like psilocybin and functional fungi. As individuals become more aware of the potential side effects and risks associated with pharmaceutical drugs, there appears to be a growing inclination towards alternative treatments, including microdosing psychedelics, that peer-reviewed clinical research is showing great promise in treating depression, anxiety, and post-traumatic stress disorder (PTSD).

Discover Benefits
of Psilocybin

Psilocybin Mushrooms (Psilocybe Cubensis)

  • 99 Ongoing Clinical Trials
  • Depression / Anxiety
  • Substance Use Disorder
  • Post Traumatic Stress Disorder